Glenn Boehnlein
Member of the Audit Committee and Operations & Innovation Committee Board member since 2026
Mr. Boehnlein has extensive experience as a public company executive at one of the world’s largest global medical technology companies, leading a complex organization through growth and scale, and provides valuable medical technology, financial, and M&A experience to the Board.
Career Highlights:
- Former Vice President, Chief Financial Officer at Stryker Corporation (2016 to 2025), a global leader in medical technologies, and Advisor to the Chief Executive Officer at Stryker (2025 to 2026).
- Chief Financial Officer and Vice President of the MedSurg and Neurotechnology Group at Stryker (2011 to 2015) and Chief Financial Officer of the Endoscopy Division at Stryker (2003 to 2010).
- Chief Financial Officer of MyPrimeTime, a media company (2000 to 2003).
- Earlier role as a Partner at Arthur Andersen LLP, an accounting firm, leading the San Francisco Technology Industry Practices.
Other Directorships – Current:
- Board of Directors of Agilent Technologies, Inc., a publicly traded analytical and clinical laboratory technologies company, since 2026.
- Inogen, Inc., a publicly traded medical technology company focused on the development, manufacture, and commercialization of respiratory products (since 2022), and currently serves as Chair of Inogen’s Audit Committee.
- Sutter Health, a private company (since 2024).
Key Experience and Qualifications:
- Executive leadership of a complex, global, medical technology company.
- Audit and financial leadership experience at public medical technology companies.
- M&A and strategic transactions.
Education:
- B.P.A. and M.P.A. in Professional Accountancy from Mississippi State University
- Certified Public Accountant (inactive)